A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Erdheim-Chester disease
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 Mar 2017 Status changed from recruiting to suspended.
- 21 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.